Dave Michalovich

SVP Precision Medicine

As Senior Vice President of Precision Medicine, Dave Michalovich is responsible for driving BenevolentAI’s precision medicine strategy, taking a patient-centric approach to understanding disease endotypes, mechanisms and targets, and applying computational biology, genomics and genetics to drug discovery. 

Dave has 25 years of experience in pharma and biotech. Before joining BenevolentAI, he served as a Senior Scientific Director at GlaxoSmithKline where he led discovery teams in the adaptive immunity research unit and respiratory therapeutic area. He has previously held positions at Syntaxin, Curidium Medica, SmithKline Beecham and Inpharmatica Ltd, where he co-developed the cheminformatics database ChEMBL, which is now used worldwide. Dave has authored over 30 peer-reviewed publications and two book chapters.

Dave holds a BSc in microbiology from the University of Reading, and spent a year as a Graduate Biologist at the European Molecular Biology Laboratory (EMBL) Data Library in Heidelberg. He earned his PhD in the laboratory of Gene Structure and Expression at the National Institute for Medical Research in London, and conducted post-doctoral research on axonal guidance mechanisms at King's College London.